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Abstract
Background: Tritrichomonas foetus is a sexually transmitted protozoon that causes reproductive failure, among
cattle, so disruptive that many western US states have initiated control programs. Current control programs are
based on the testing and exclusion of individual bulls. Unfortunately, these programs are utilizing screening tests
that are lacking in sensitivity. Blanket treatment of all the exposed bulls and adequate sexual rest for the exposed
cows could provide a more viable disease control option. The objectives of this study were twofold. The first objective
was to demonstrate effectiveness for metronidazole treatment of a bull under ideal conditions and with an
optimized treatment regime. This type of study with a single subject is often referred to as an n-of-1 or single
subject clinical trial. The second objective of the current study was to review the scientific basis for the banning
of metronidazole for use in Food Animals by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA).
Results: Results from an antimicrobial assay indicated that metronidazole at a concentration of 0.5 μg/mL successfully
eliminated in vitro protozoal growth of bovine Tritrichomonas foetus. The estimated effective intravenous dose was
two treatments with 60 mg/kg metronidazole, 24 h apart. A bull that had tested positive for Tritrichomonas foetus
culture at weekly intervals for 5 weeks prior to treatment was negative for Tritrichomonas foetus culture at weekly
intervals for five consecutive weeks following this treatment regimen. An objective evaluation of the published
evidence on the potential public health significance of using metronidazole to treat Tritrichomonas foetus in bulls
provides encouragement for veterinarians and regulators to consider approaches that might lead to permitting the
legal use of metronidazole in bulls.
Conclusion: The study demonstrated successful inhibition of Tritrichomonas foetus both in vitro and in vivo with
metronidazole. The current status of metronidazole is that the Animal Medicinal Drug Use Clarification Act of 1994
prohibits its extra-label use in food-producing animals. Veterinarians and regulators should consider approaches
that might lead to permitting the legal use of metronidazole in bulls.
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Background
Tritrichomonas foetus TF) is a sexually transmitted
protozoon that causes reproductive failure so disruptive
among cattle that virtually all US states west of the
Mississippi River have initiated control programs [1].
Each of these control programs is based on the testing
and exclusion of individual bulls. The resultant loss of
bulls as a result of the various test and removal programs
has been substantive. For example, over 1000 bulls were
culled from Texas ranches in 2010 [2]. In addition to the
cost of replacing bulls, test and removal programs will
often fail to control TF in cattle populations because the
sensitivity of the testing is low [1]. The pursuit of a more
sensitive test has been vigorous but results, thus far, show
that newer tests can be very sensitive in experimental con-
ditions, but show limited success in field conditions [3, 4].
The current standard for regulatory testing in Texas is a
single negative polymerase chain reaction (PCR) test
which, based on the available literature, has a test sensitiv-
ity very likely in the 70–80% range. While the identifica-
tion of infected individuals is currently lacking sensitivity,
the identification of infected populations can be very ac-
curate. The accuracy of a test for identifying infected
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populations depends on test specificity, the disease in-
fectivity and the population size [5]. For detecting TF-
infected herds, every bull could be cultured and posi-
tive cultures confirmed by a TF-specific PCR thus
resulting in a nearly perfect specificity for individual
bulls [6]. Thus, multiple sire breeding groups could be
evaluated very accurately because the disease is highly
contagious and multiple bulls would be affected. Blan-
ket treatment of all the exposed bulls and adequate sex-
ual rest for the exposed cows could provide a more
viable disease control option than test and removal. In
the early 1980’s, both dimetridazole (50 mg/kg PO for 5
days) and ipronidazole (60 g IM) were shown to be
100% effective against TF in bulls [7, 8]. At that time,
blanket treatments were recommended. Since then, the
nitroimidazole family, including dimetridazole and
ipronidazole, has been prohibited from use in animals
intended for consumption as food. In humans, another
nitroimidazole, metronidazole, is considered nearly
100% effective for Trichomonas vaginalis (VG) by the
Centers for Disease Control and Prevention (CDC) and
is the sole recommended treatment. Very few other
drugs have even been evaluated [9]. The CDC also rec-
ognizes the low sensitivity of testing, and recommends
that all sexual partners of a patient with TV be treated
with metronidazole [10]. Despite the obvious potential,
no treatment trials for TF have been found in the avail-
able veterinary literature since 1985, leaving this treat-
ment potential untapped.
In 1954, Rhone-Poulenc discovered that azomycin (2-
nitroimidazole), isolated from a Streptomycesspecies, had
weak in vitro activity against TV. The company investi-
gated over 200 related chemicals and discovered that
metronidazole (1-(2-hydroxyethyl)-2-methyl-5-nitroimi-
dazole) was the most promising trichomonacide [11].
Over six decades later metronidazole is still widely used. It
has a limited spectrum that encompasses various proto-
zoans (like Tritrichomonas spp.) as well as most Gram-
negative and Gram-positive anaerobic bacteria. It is both
cost effective and readily available. It is currently produced
and marketed in various forms for human use, including
as a solution for intravenous injection. Under the provi-
sions of AMDUCA and 21 Code of Federal Regulations
(CFR) part 530, the FDA can prohibit extralabel use of an
entire class of drugs in selected animal species. Accord-
ing to this mandate, nitroimidazoles (including metro-
nidazole) are not allowed extralabel in any food-producing
animal. Because no products containing metronidazole are
currently approved in the U.S., this ban on extralabel use is
effectively a ban on all use in cattle.
The first objective of this study was to perform in vitro
susceptibility testing for metronidazole on bovine-origin
TF and to use these data along with published pharma-
cokinetic data in cattle to estimate an effective dose and
to pilot test the dose in the infected bull. Showing that
metronidazole could potentially be efficacious in vivo for
treatment of TF infections would complement the second
objective which was to review the scientific information
relevant to the banning of metronidazole in Food Animals
by the Animal Medicinal Drug Use Clarification Act of
1994 (AMDUCA).
Methods
Procedure 1: in vitro susceptibility assay
Commercial injectable 5 mg/mL metronidazole solution
was diluted with isotonic saline into five stock solutions:
0.01 mg/mL, 0.005 mg/mL, 0.0025 mg/mL, 0.00125 mg/
mL, and 0.000625 mg/mL. From each stock solution,
0.2 mL was added to five separate commercially available
culturing pouches, 1 each containing 3.8 mL of culture
media, for a total of five culture media pouches per
stock concentration. Five culture media pouches were
used as a control group, and were inoculated with
0.2 ml of isotonic saline. Final concentrations of metro-
nidazole in the pouches were: 0 μg/ml, 0.0313 μg/mL,
0.0625 μg/mL, 0.125 μg/mL, 0.25 μg/mL and 0.5 μg/mL.
A second researcher, who was masked to drug concen-
trations, inoculated each pouch with 20,000 viable or-
ganisms from a single standard culture taken from the
bull that had been designated for a treatment trial.
Organism numbers were estimated using a Neubauer
Chamber.2 Pouches were contained in an upright pos-
ition and incubated at 35 °C. Pouches were evaluated for
TF viability at 24-h intervals for 7 days by the masked
researcher. An absence of all typical TF motility was used
as the criterion for growth inhibition. The evaluation at
48 h was chosen as the critical cut-point.
Procedure 2: treatment of infected Bull
An 891 kg, Charolais-cross bull identified as positive for
TF by the Texas Bovine Trichomoniasis Control Program
was selected. The bull had previously been cultured posi-
tive multiple times over 6 months. The bull was restrained
in a squeeze chute and an intravenous catheter was placed
in the left jugular vein. A volume of 10.8 l of 5 mg/mL
(approximately 60 mg/kg; 54 g total dose) commercially
available metronidazole solution was administered intra-
venously over a period of one hour. The treatment was
repeated 24 h later. Pre-treatment cultures were taken
at weekly intervals for 5 weeks including just prior to
the first intravenous injection. Post-treatment cultures
were obtained on the 6th day following the second
intravenous injection and then at weekly intervals for 4
weeks. The clinical cultures, including both pre- and
post-treatment were performed as recommended in the
Texas Trichomonas Bull Test Program. Briefly, an aggres-
sive scraping was collected from the fornix of the prepuce
using an infusion pipette and a 12-ml syringe providing
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negative pressure during the scraping. The collection of
material from the scraping was immediately inoculated
into an InPouchTF1 culture system and cultured in an up-
right position for 7 days at 37 oC. Every 24 h, the culture
media was examined under a light microscope and cul-
tures were considered positive when the presence of any
typical TF motility was observed. Potential bias was con-
trolled by having the clinician most experience with sam-
ple collection and culture evaluations (JAT) perform all
the testing and evaluation. The study also avoided bias by
using culture rather than PCR. Test results by PCR can be
falsely positive as a result of non-viable organisms.
Statistics
Proportions of viable cultures were compared using
Bayesian methods. For i = 2 proportions, the counts of
positive results (ri) were modeled as binomial with rate
parameter μi and number of trials (Ni) such that:
riebinomial μi; ;Nið Þ
r and N were provided by the data and μ was assigned
a prior that was vague normal with a mean of zero and
precision of 0.0001, on the logit scale. To compare the
two proportions, the odds ratio was estimated, and the
odds ratio was considered statistically significant at
P< 0.05; if the exceedance probability was greater than
95% that the odds ratio drawn from the full posterior
distribution was greater than 1. In the use of Bayesian P-
values this is called the posterior predictive P-value [12].
Results
In vitro susceptibility assay
Culture viability at 48 h was 0% for 0.5 μg/mL metro-
nidazole and 100% for 0 μg/mL metronidazole. The
highest two concentrations were each more likely to
result in a non-viable culture than each of the lower
concentrations (P< 0.05; Table 1).
Treatment of infected Bull
All five pre-treatment cultures were positive, and all five
post-treatment cultures were negative. The proportions
of positive culture before and after treatment were
significantly different (P < 0.05).
Discussion
N-of-1 or single subject clinical trials consider an indi-
vidual patient as the sole unit of observation in a study
investigating the efficacy or side-effect profiles of inter-
ventions. The ultimate goal of an n-of-1 trial is to deter-
mine the optimal or best intervention for an individual
patient using objective data-driven criteria. The first goal
of this study was to demonstrate efficacy of metronida-
zole in an individual bull. The evaluation used a 48-h
susceptibility assay for TF isolated from the patient and
subsequent treatment of the patient with the dose of
metronidazole that was estimated to be effective. In the
opinion of the authors, a clinical trial with more animals
was not warranted prior to a full discussion among the
veterinary profession regarding the potential for disease
control and the current legal implications for such treat-
ment. This discussion should include a critical review of
the published literature relevant to the legal status of
metronidazole use in cattle.
Metronidazole at a concentration of 0.5 μg/mL suc-
cessfully eliminated viable protozoal growth of bovine
TF in 5/5 cultures and a concentration of 0.25 μg/mL
eliminated viable protozoal growth in 4/5 cultures after
48-h. Based on published pharmacodynamics parame-
ters, a dose of 60 mg/kg would provide a blood concen-
tration of greater than 0.25 μg/mL for nearly a 24-h
period [13]. A second dose at 24 h was given and should
have maintained a blood concentration of greater than
0.25 μg/mL for most of a 48-h period. This dose regimen
resulted in repeated negative cultures in a previously cul-
ture-positive bull. Studies are needed to verify the ef-
fectiveness with this regimen in a population of bulls,
but this n-of-1 study demonstrates feasibility. More
than 40 years ago, a small number of studies showed
promising potential for treating TF in bulls with metro-
nidazole [14–17]. While treatments appeared to be ef-
fective, problems resulted from the poor solubility and
the acidity of metronidazole in solution. Complications
following intravenous treatment included tachypnea
and tachycardia and muscle trembling [14, 17]. The
product evaluated in the current study, while dilute and
requiring a large volume for injection, was isosmotic and
pH buffered. The bull being treated maintained steady
heart and respiratory rates during the treatment.
Metronidazole is currently available as an approved
human drug, in a formulation that was well-tolerated by
the patient in the current study. However, the FDA cur-
rently prohibits extralabel use of the entire family of
nitroimidazoles in food-producing animals. The FDA
prohibits drugs based on either of two statutes: either
“an acceptable analytical method (for evaluating tissue
Table 1 Culture viability by metronidazole concentration
Metronidazole concentration Viable cultures at 48 h
0.0 μg/ml 5/5a
0.0313 μg/mL 4/5a
0.0625 μg/mL 4/5a
0.125 μg/mL 5/5a
0.25 μg/mL 1/5b
0.5 μg/mL 0/5b
Proportions with different superscripts were significantly different (P < 0.05)
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residues) needs to be established and such a method has
not or cannot be established” or “the extra-label use of the
drug or drug class presents a public health risk” [18]. It is
thought that nitroimidazoles are banned due to the latter
statute, namely their potential to cause cancer in humans.
The most desirable solution to improve reproductive
health and TF control would be the development of a
new animal drug with label indications for treatment of
TF in bulls. Alternatively, an expedient solution would
be to remove metronidazole from the banned list or,
more specifically, metronidazole treatment of TF in bulls
could be exempted. The AMDUCA, Section 530.21
states that “a prohibition may be a general ban on the
extralabel use of the drug or class of drugs or may be
limited to a specific species, indication, dosage form,
route of administration, or combination of factors.”
Logically, the inverse would also be true and that a lim-
ited exemption could be permitted. An exemption for
this dosage form, species, and indication would not con-
stitute a risk to public health because humans could be
protected from exposure from meat. First, the dosage
form requires large volume of intravenous injection
which is very likely to remain under control of licensed
veterinarians who have become adequately sensitized to
the issues of tissue residues. Second, the veterinarian
can recommend prolonged drug withdrawal times and
these should be acceptable to informed owners because
these bulls will usually remain in service for at least several
months of a breeding season. Third, the number of bulls
that will be treated will be relatively few. For bulls that do
not respond to treatment, a satisfactory withholding time
for slaughter should be established.
While the veterinary profession could prevent human
exposure to meat residues of metronidazole or its metabo-
lites, others may choose to debate the entire body of evi-
dence that metronidazole is a human carcinogen. There is
a large body of literature to consider before engaging in
this debate. As early as 1977, the International Agency for
Research in Cancer (IARC) [19] had decided that metro-
nidazole was carcinogenic in rodents, citing Rustia and
Shubik [20]. The countering viewpoint was presented im-
mediately and vigorously in 1977 [21], 1979 [22] and 1981
[23]. However, the IARC confirmed their decision in 1982
[24], citing a second paper by Rustia and Shubik [25] and
their earlier decision [19]. In 1986, the FDA provided con-
siderable discussion to support the decision to remove a
nitroimidazole, dimetridazole, as an approved animal drug
[26]. The cited work included five papers said to show that
metronidazole was carcinogenic in rodents [20, 25, 27–
29]. By 1987, the IARC repeated their earlier assessment
and cited a list [27, 28, 30] virtually identical to the refer-
ences provided by the FDA [31]. In disputing the cancer
risk in rodents, Roe provides very specific criticisms,
claiming that virtually all long-term exposures of rodents
to metronidazole show an increase in both life span and
weight gain and these two factors were the more likely
causes of any variation in cancer incidence [32]. In one
study, the median survival time increased from 83 weeks
for the control rats (did not get metronidazole) to
122 weeks for rats receiving metronidazole [25]. Thus,
the treated animals lived nearly 50% longer. This poten-
tial bias is more than just increased time-at-risk for the
treated animals because the rate of cancer development
(i.e., incident cases per unit time) increases with age.
Weight gain has also had a strong association with can-
cer in rodents with the rate of cancer elevated 6–8
times when mice are fed ad libitum versus restricted
feeding [33]. The debate as to the carcinogenicity of
metronidazole in rodents will not to be satisfactorily re-
solved, based on the conflicting and often biased litera-
ture that currently exists. In more recent years, the
debate has centered on the broader issues such as the
usefulness of rodent studies in evaluating human health
risks, even if the risks estimated for rodents are accur-
ate for the reported doses. There is an overwhelming
number of drugs currently used with evidence of car-
cinogenicity in rodents. For example, one review of 535
marketed pharmaceuticals showed that more than half
of them had been judged carcinogenic in rodents [34].
Recently, several papers have reviewed the history and
problems using largely unstandardized testing and ana-
lyses of results from cancer studies in rodents [35–37].
Emerging from this evaluation has been a general criti-
cism of inferring human cancer risk from rodent stud-
ies as well as recommendations to standardize the use
of rodent studies in cancer risk assessment [38]. There
have been epidemiologic studies evaluating the human
cancer risk and metronidazole is not considered a risk
factor for human cancer [39]. This entire body of litera-
ture should be re-evaluated and we encourage the vet-
erinary profession to be aware of these issues and join
the debate. We also urge the FDA to grant the veterinary
profession an opportunity to treat TF in bulls with
metronidazole.
Conclusion
The current study showed potential for treating TF in
bulls with metronidazole.
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